Otros idiomas Gossamer Bio, Inc.

Acciones

GOSS

US38341P1021

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 06/02/2026			Variación 5 días	Varia. 1 de enero.
2,260 ^USD	-7,19 %		-0,88 %	-27,10 %

28/01	GOSSAMER BIO, INC. : Barclays mantiene una recomendación de compra.	ZM
09/12	Gossamer Bio anuncia concesión de incentivos conforme a la norma 5635(c)(4) de cotización de Nasdaq	RE

Otros idiomas

08/01	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22/12	Gossamer Bio, Inc.(NasdaqGS:GOSS) added to S&P Biotechnology Select Industry Index
22/12	Gossamer Bio, Inc.(NasdaqGS:GOSS) added to NASDAQ Biotechnology Index
09/12	Gossamer Bio announces inducement grant under Nasdaq Listing Rule 5635(c)(4)
09/12	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
24/11	Gossamer Bio to Participate in Upcoming Investor Conferences
07/11	Gossamer Bio announces inducement grant under Nasdaq Listing Rule 5635(c)(4)
07/11	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/11	Gossamer Bio to Participate in Upcoming Investor Conferences
05/11	Gossamer Bio : November 2025 Corporate Presentation (666053)
05/11	Gossamer Bio: Q3 Earnings Snapshot
05/11	Gossamer Bio's Q3 net loss widens to $48.2 mln
05/11	Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
05/11	Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
07/10/25	How companies are steering IPO plans amid US government shutdown
25/09/25	Sector Update: Health Care Stocks Decline Premarket Thursday
25/09/25	Gossamer Bio Secures Option to Acquire Respira Therapeutics
25/09/25	Respira therapeutics says enters into agreement granting Gossamer option to acquire co from Samsara BioCapital
25/09/25	Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
25/09/25	Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
22/09/25	Gossamer Bio, Inc. Announces Presentations At the European Respiratory Society Congress 2025
22/09/25	Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
10/09/25	Gossamer Bio announces inducement grant under Nasdaq Listing Rule 5635(c)(4)
10/09/25	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/09/25	Gossamer Bio Shares Rise After UBS Upgrade, PT Increase

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Artículos de MarketScreener Estrategias MarketScreener Ideas de trading

Otros idiomas Gossamer Bio, Inc.

Acciones

GOSS

US38341P1021

Biotecnología e investigación médica

Otros idiomas

Filtros